SLS - NASDAQ

SELLAS Life Sciences Group, Inc.

SLS·NASDAQ

$8.19

-1.7%

HealthcareBiotechnology

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.17B

EPS-0.2500

P/E Ratio-32.76

Earnings Date08/11/2026

78.34M

Assets

303%

3Y+274.0%

5Y+70.0%

10Y+19.0%

7.47M

Total Liabilities

-25%

3Y-54.0%

5Y-59.0%

10Y-80.0%

70.87M

Total Equity

649%

3Y+1361.0%

5Y+153.0%

10Y+147.0%

SELLAS Life Sciences Group, Inc. Funding & Solvency Profile

SLS · NASDAQ

Current Assets

Cash & Cash Equivalents71.89M

Net Receivables0.00

Inventory0.00

Other Current Assets3.32M

Total Current Assets75 M

Non-Current Assets

Property, Plant & Equipment963.00K

Goodwill & Intangible Assets1.91M

Long-Term Investments0.00

Other Non-Current Assets257.00K

Total Non-Current Assets1 M

Total Assets

78.34M

Financial Health Analysis

Current Ratio

10.72x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.11x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

68 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

96% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

SELLAS Life Sciences Group, Inc. Balance Sheet

SLS • NASDAQ

SELLAS Life Sciences Group, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	71.9M	13.9M	2.5M	17.1M	21.5M	35.3M	7.3M	5.3M	2.3M	18.1M	29.7M	23.7M	47.8M	32.8M	11.4M	6.9M	5.7M	9.9M	1.8M	2K
Short-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7M	0.0	0.0	0.0	0.0	10M	0.0
Cash & Short-Term Investments	71.9M	13.9M	2.5M	17.1M	21.5M	35.3M	7.3M	5.3M	2.3M	18.1M	29.7M	23.7M	47.8M	35.5M	11.4M	6.9M	5.7M	9.9M	11.7M	2K
Net Receivables	0.0	0.0	0.0	0.0	0.0	1.1M	308K	0.0	0.0	0.0	0.0	1.8M	3.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8M	3.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	0.0	0.0	0.0	0.0	0.0	1.1M	308K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	573K	0.0	0.0	0.0	-19.5M	655K	386K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	2.3M	542K	301K	1.6M	365K	473K	210K	337K	332K	1.4M	1.2M	1.4M	535K	276K	150K	120K	73K	22K	0.0
Other Current Assets	3.3M	100K	100K	330K	27K	130K	-389K	291K	10.4M	85K	22.5M	1.6M	200K	101K	101K	0.0	0.0	0.0	0.0	0.0
Total Current Assets	75.2M	16.3M	3.2M	17.8M	23M	36.9M	8.2M	5.8M	13.1M	37.5M	53.6M	29M	53.5M	36.1M	11.8M	7M	5.8M	9.9M	11.7M	2K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	963K	925K	858K	874K	723K	896K	217K	0.0	0.0	199K	335K	555K	665K	29K	393K	419K	432K	414K	344K	0.0
Goodwill	1.9M	1.9M	1.9M	1.9M	1.9M	1.9M	1.9M	1.9M	1.9M	5.9M	5.9M	6.1M	5.9M	5.9M	5.9M	0.0	0.0	0.0	0.0	0.0
Intangible Assets	0.0	0.0	0.0	0.0	0.0	5.7M	5.7M	8.5M	17.6M	22.1M	22.1M	44.8M	27.8M	12.9M	12.9M	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	1.9M	1.9M	1.9M	1.9M	1.9M	7.6M	7.6M	10.4M	19.5M	28M	28M	50.8M	33.7M	18.8M	18.8M	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	0.0	0.0	0.0	-184K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	74K	3K	0.0	0.0	0.0	0.0	0.0
Tax Assets	0.0	0.0	0.0	184K	152K	0.0	0.0	1.4M	0.0	0.0	0.0	0.0	0.0	-74K	-13.3M	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	257K	466K	275K	399K	594K	614K	536K	-765K	925K	96K	171K	87K	115K	74K	13.3M	16K	16K	16K	66K	0.0
Total Non-Current Assets	3.1M	3.3M	3M	3.2M	3.4M	9.1M	8.4M	11.1M	20.4M	28.3M	28.5M	51.5M	34.5M	18.9M	19.2M	435K	448K	430K	410K	0.0
Other Assets	0.0	-200K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Assets	78.3M	19.4M	6.2M	20.9M	26.4M	46M	16.6M	16.9M	33.5M	65.8M	82.1M	80.5M	88M	55M	31M	7.5M	6.3M	10.4M	12.1M	2K
LIABILITIES
CURRENT LIABILITIES
Total Payables	2.9M	3.5M	5.6M	3.4M	2.1M	4.7M	3.9M	3.8M	11.7M	1.8M	26.6M	2.3M	2.7M	2M	2.2M	724K	625K	394K	80K	0.0
Accounts Payable	2.9M	3.5M	5.6M	3.4M	2.1M	4.7M	3.9M	3.8M	11.7M	0.0	1.6M	2.3M	2.7M	2M	2.2M	724K	625K	394K	55K	0.0
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	50K	0.0
Accrued Expenses	0.0	3.6M	6.1M	6.3M	989K	907K	565K	2.2M	3M	249K	1.5M	2.2M	2M	1.8M	1.4M	740K	659K	531K	360K	0.0
Short Term Debt	544K	0.0	0.0	0.0	198K	0.0	217K	0.0	8.4M	1.7M	4.7M	3.9M	2.2M	6K	500K	51K	52K	17K	0.0	0.0
Capital Lease Obligations (Current)	0.0	544K	446K	372K	0.0	166K	217K	0.0	0.0	0.0	0.0	0.0	6K	6K	35K	51K	52K	17K	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	426K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	25K	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	5.6M	0.0	0.0	4.3M	5.2M	30.3M	15.7M	8.7M	935K	816K	1.1M	1.1M	974K	0.0	0.0
Other Current Liabilities	3.5M	1.8M	1.5M	5.5M	1.7M	1M	389K	8K	1.5M	2M	24.2M	18.9M	55.6M	11.2M	6.3M	3.5M	4.1M	428K	884K	0.0
Total Current Liabilities	7M	9.5M	13.7M	15.5M	5M	12.3M	5.3M	6M	24.6M	30.4M	57.1M	27.2M	62.4M	15.9M	11.2M	5M	5.5M	1.4M	1.3M	0.0
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6M	5.7M	0.0	4.5M	7.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	-184K	0.0	0.0	0.0	0.0	1.3M	-5.7M	-10.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	184K	152K	239K	262K	357K	1.7M	5.7M	5.4M	5.1M	5.1M	5.1M	5.1M	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	0.0	4K	336K	4.7M	5M	5.3M	2.6M	-5.7M	6.1M	6.7M	6.8M	6.2M	4.6M	0.0	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	457K	457K	460K	577K	1.1M	5.8M	5.2M	5.7M	6.9M	6.8M	11.6M	16.2M	19.6M	11.3M	9.7M	20K	36K	4K	0.0	0.0
Capital Lease Obligations	457K	1M	906K	945K	610K	991K	217K	0.0	0.0	0.0	0.0	0.0	32K	57K	67K	71K	88K	4K	0.0	0.0
Total Liabilities	7.5M	10M	14.2M	16.1M	6.1M	18.1M	10.5M	11.7M	31.5M	37.2M	68.6M	43.4M	82.1M	27.2M	20.9M	5M	5.5M	1.4M	1.3M	0.0
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.8M	-3.8M	-3.8M	-3.8M	-3.8M	-3.8M	-3.8M	0.0	0.0	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	374K	0.0	0.0	0.0	0.0	0.0	0.0
Common Stock	15K	7K	3K	2K	2K	1K	5K	2K	1K	15K	15K	12K	10K	8K	5K	2K	2K	1K	1K	0.0
Additional Paid-In Capital	345.8M	257.6M	209.3M	184.8M	158.9M	145.9M	107.2M	87.1M	56.3M	25.4M	296.7M	256.4M	188.6M	132.2M	81.2M	62M	44.5M	34.3M	21.8M	2K
Retained Earnings	-275M	-248.1M	-217.2M	-179.9M	-138.6M	-117.9M	-101.1M	-81.9M	-54.2M	-302.9M	-279.4M	-215.5M	-178.9M	-102.2M	-67.2M	-55.7M	-43.8M	-25.4M	-11M	0.0
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6M	-657K	-491K	-320K	-158K	0.0	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	70.9M	9.5M	-8M	4.9M	20.3M	28M	6.1M	5.2M	2.1M	28.7M	13.5M	37.1M	5.9M	27.8M	10.1M	2.4M	741K	9M	10.8M	2K
Total Equity	70.9M	9.5M	-8M	4.9M	20.3M	28M	6.1M	5.2M	2.1M	28.7M	13.5M	37.1M	5.9M	27.8M	10.1M	2.4M	741K	9M	10.8M	2K
SUMMARY
Total Liabilities & Equity	78.3M	19.4M	6.2M	20.9M	26.4M	46M	16.6M	16.9M	33.5M	65.8M	82.1M	80.5M	88M	55M	31M	7.5M	6.3M	10.4M	12.1M	2K
Total Investments	0.0	0.0	0.0	-184K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8M	3K	0.0	0.0	0.0	10M	0.0
Total Debt	1M	1M	906K	945K	808K	991K	217K	0.0	11M	16.4M	4.7M	8.4M	9.9M	57K	567K	71K	88K	21K	0.0	0.0
Net Debt	-70.9M	-12.9M	-1.6M	-16.2M	-20.6M	-34.3M	-7.1M	-5.3M	8.7M	-1.7M	-25M	-15.2M	-37.9M	-32.8M	-10.9M	-6.8M	-5.6M	-9.8M	-1.8M	-2K
Shares Outstanding	105,404,166	105,404,166	105,404,166	105,404,166	105,404,166	105,404,166	105,404,166	105,404,166	105,404,166	105,404,166	105,404,166	105,404,166	105,404,166	105,404,166	105,404,166	105,404,166	105,404,166	105,404,166	105,404,166	105,404,166

SEC Filings

SLS - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 02, 2026	June 02, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 23, 2026	June 16, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 19, 2026	March 19, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 19, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 11, 2026	March 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 08, 2026	January 07, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 12, 2025	November 12, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 12, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 462 filings

Related Guides

Blog Categories

Continue your SLS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.